Information Links

http://www.florida-institute.com/index.cfm?fuseaction=news.viewitem&newsID=99
Modulation Therapeutics Receives Seed Funding through Florida Institute.

Tampa-Based Company is Eleventh to Receive Capital through the SCAP Program

http://www.themmrf.org/about-the-mmrf/powerful-news/press-releases/multiple-myeloma-research-foundation-mmrf-awards-funding-to-modulation-therapeutics-for-innovative-cancer-treatment.html
Multiple Myeloma Research Foundation (MMRF) Awards Funding to Modulation Therapeutics for Innovative Cancer Treatment. MMRF Biotech Investment Award Bolsters Development of Novel Myeloma Therapies.

http://www.ncbi.nlm.nih.gov/pubmed/21980133
Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype.
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Mol Cancer Ther. 2011 Dec;10(12):2257-66. Epub 2011 Oct 6. PubMed PMID: 21980133; PubMed Central PMCID: PMC3237739.

http://www.ncbi.nlm.nih.gov/pubmed/19671765
HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.
Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. Mol Cancer Ther. 2009 Aug;8(8):2441-51. Epub 2009 Aug 11. PubMed PMID: 19671765; PubMed Central PMCID: PMC2761715.

http://www.ncbi.nlm.nih.gov/pubmed/16537560
Synthetic D-amino acid peptide inhibits
tumor cell motility on laminin-5. Sroka TC, Pennington ME, Cress AE. Carcinogenesis. 2006 Sep;27(9):1748-57. Epub 2006 Mar 14. PubMed PMID: 16537560

Modulation Therapeutics receives seed funding through Florida Institute. Feb. 14th, 2013
Modulation Therapeutics is awarded 2nd SBIR Phase I grant to determine the role of MTI-101 treatment in modulating the bone marrow niche. Oct. 25th, 2012
Modulation Therapeutics is awarded a Phase I SBIR grant to evaluate PK of MT-101 and analogs of MTI-101. Sept. 10th, 2012
Modulation Therapeutics in collaboration with Moffitt Cancer Center is awarded a Bankhead Coley grant for preclinical testing of MTI-101 in Acute Myeloid Leukemia. June 2012
Multiple Myeloma Research Foundation (MMRF) Awards Funding to Modulation Therapeutics for Innovative Cancer Treatment. June 2012
Modulation Therapeutics establishes research facilities at USF Connect research park Jan. 2012